Home How It Works Goals Protocols Lab Tests Peptides Blog About Log In Get Started

GH Secretagogue — GHRH Analog + GHRP

CJC-1295 / Ipamorelin — Combination Growth Hormone Secretagogue Therapy

CJC-1295 (without DAC) paired with ipamorelin is the most widely used GH secretagogue combination in clinical telehealth settings. The two peptides target distinct receptor pathways — GHRH and ghrelin — producing synergistic, pulsatile GH release that preserves physiologic feedback regulation. Evidence level: Level II–III (Phase 2 human pharmacology + preclinical selectivity data).

Start a Consultation Back to GH Secretagogues

Mechanism of action

What CJC-1295 and ipamorelin are — and why they are used together.

CJC-1295 and ipamorelin are two structurally and mechanistically distinct peptides that are almost always used in combination. Understanding each compound's individual mechanism explains why the pairing is pharmacologically logical and why the combination is favored over either agent alone.

CJC-1295 (Modified GRF 1-29) — GHRH Analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically modeled on the biologically active 1–29 amino acid fragment of endogenous GHRH. The version used in combination protocols — CJC-1295 without DAC, also called Modified GRF 1-29 (Mod GRF 1-29) — retains four amino acid substitutions that improve enzymatic stability and increase half-life from approximately 2 minutes (endogenous GHRH) to approximately 30 minutes. It binds to GHRH receptors on pituitary somatotroph cells, triggering intracellular cAMP signaling and GH secretion.

CJC-1295 WITH DAC vs. WITHOUT DAC — Critical Distinction

The Drug Affinity Complex (DAC) modification attaches a lysine-maleimide linker to CJC-1295 that enables covalent binding to serum albumin, extending the half-life to approximately 6–8 days. CJC-1295 with DAC produces sustained, prolonged GH and IGF-1 elevation without discrete pulses — a profile sometimes called a "GH bleed." The without-DAC version is preferred in combination with ipamorelin precisely because its shorter action preserves the pulsatile pattern of endogenous GH release, maintaining physiologic feedback via somatostatin. Most clinical telehealth protocols use the without-DAC form.

Ipamorelin — Selective Growth Hormone Releasing Peptide (GHRP)

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist at the GHS-R1a receptor, also known as the ghrelin receptor. It is classified as a GHRP — growth hormone releasing peptide. Its clinical distinction is its exceptional receptor selectivity: unlike older GHRPs such as GHRP-2 and GHRP-6, ipamorelin produces potent GH release without meaningfully elevating cortisol, ACTH, or prolactin. The foundational characterization study (Raun et al., 1998, PMID: 9849822) coined it "the first selective growth hormone secretagogue." This selectivity makes it substantially more tolerable for long-term clinical protocols.

Synergistic Dual-Pathway Activation

The combination works because GHRH receptor activation (via CJC-1295) and GHS-R1a activation (via ipamorelin) utilize distinct intracellular signaling cascades at the pituitary somatotroph level. GHRH acts primarily through the adenylyl cyclase/cAMP/PKA pathway; ghrelin receptor agonism acts through Gq/phospholipase C/IP3 signaling. Co-activation of both pathways produces a GH pulse significantly greater than either agent individually. The effect is synergistic, not merely additive, based on mechanistic data from preclinical pituitary cell studies.

Downstream IGF-1 Production

GH released from the pituitary travels via circulation to the liver, where it stimulates hepatic production of insulin-like growth factor-1 (IGF-1). IGF-1 is the primary mediator of many of GH's anabolic and body composition effects — including lean muscle accrual, lipolysis in visceral adipose tissue, connective tissue synthesis, and collagen deposition. IGF-1 also participates in a negative feedback loop, signaling the hypothalamus to increase somatostatin (which suppresses further GH release), thereby maintaining physiologic regulation even when GH output is pharmacologically elevated.

Ipamorelin's Appetite Effect

Because ipamorelin acts at the ghrelin receptor (GHS-R1a), and ghrelin is the body's primary orexigenic ("hunger") hormone, ipamorelin use may be associated with increased appetite — particularly when dosed at or near meal times. This effect is more prominent in higher-dose protocols. In clinical settings, the combination is typically administered before sleep or in a fasted state to align with natural GH pulsatility and to moderate appetite-related effects. Patients should discuss this with their clinician when designing a protocol.

How it may work

Pulsatile GH release and the IGF-1 axis.

The physiologic significance of pulsatility — and why preserving it matters for clinical outcomes — is central to understanding the CJC-1295/Ipamorelin combination strategy.

Natural GH Pulsatility

Endogenous growth hormone is secreted in discrete pulses — approximately 6–12 per day in healthy young adults, with the largest pulse occurring 60–90 minutes after sleep onset during slow-wave sleep. This pulsatile pattern is critical: continuous, non-pulsatile GH exposure leads to GH receptor downregulation and loss of sensitivity. CJC-1295 without DAC preserves this pulsatile pattern; this is a key reason it is favored over the DAC version in combination protocols.

Somatopause and Age-Related GH Decline

GH secretion declines progressively with age — a phenomenon termed somatopause — with IGF-1 levels in many adults over 40 falling below the normal range for younger adults. This decline is associated with changes in body composition (increased visceral fat, decreased lean mass), reduced bone density, altered sleep architecture, and decreased recovery capacity. GH secretagogue protocols are explored in clinical settings as a means to support physiologic GH/IGF-1 axis activity in this population.

Body Composition Effects — What Evidence Suggests

Elevated GH and IGF-1 may support: reduction in visceral adipose tissue through enhanced lipolysis; increases in lean muscle mass via protein synthesis and satellite cell activation; improved connective tissue synthesis including collagen deposition in tendons and ligaments; and enhanced post-exercise recovery. These effects are established in the context of GH deficiency treatment with recombinant HGH, and are extrapolated — with less direct evidence — to GHS protocols. Discuss with your clinician whether your specific goals align with current evidence.

Sleep Quality — A Frequently Reported Benefit

The largest endogenous GH pulse occurs during slow-wave (deep) sleep. Evidence from GH deficiency studies suggests that GH axis activity supports sleep architecture quality. Many patients in clinical GHS protocols report improved sleep quality, particularly deeper sleep and more restorative rest, within the first 2–4 weeks of nightly dosing. This effect is patient-reported and has not been formally evaluated in a controlled trial for CJC-1295/Ipamorelin specifically, but is mechanistically consistent with GH's role in sleep physiology.

Negative Feedback Preservation

Unlike exogenous recombinant HGH, which bypasses the pituitary and suppresses endogenous GH secretion, CJC-1295/Ipamorelin stimulates the pituitary to release GH within its natural regulatory framework. The resulting IGF-1 elevation feeds back to the hypothalamus, increasing somatostatin release and dampening further GH release. This negative feedback loop is preserved with GHS peptides, providing a theoretical safety advantage over exogenous HGH — though long-term comparative data are limited.

Evidence Level — Important Context

The CJC-1295/Ipamorelin combination as a paired protocol has not been evaluated in a published double-blind RCT. The evidence base consists of: a Phase 2 pharmacokinetic/pharmacodynamic study for CJC-1295 alone (Ionescu & Frohman, 2006); foundational pharmacology for ipamorelin (Raun et al., 1998); and extrapolation from tesamorelin RCT data for body composition endpoints. Clinical telehealth use is therefore based on mechanistic plausibility and limited direct human data, not controlled efficacy trial evidence.

Clinical evidence

What the research shows — and what it does not.

All PMIDs below are verified against PubMed as of May 2026. The evidence hierarchy for CJC-1295 and ipamorelin is Level II–III — Phase 2 human pharmacology and foundational preclinical pharmacology — without completed body composition RCTs.

CJC-1295 Phase 2 Human Pharmacology

PMID: 17018654 · Ionescu & Frohman, J Clin Endocrinol Metab 2006 · Evidence: Level II (Phase 2)

In a dose-escalation study of healthy adult volunteers, a single injection of CJC-1295 at 60 or 90 mcg/kg increased mean GH concentrations by 46% and IGF-1 levels by 45%, with effects persisting for 6 days post-injection. Critically, pulsatility of GH secretion was preserved throughout the observation period — both pulse frequency and amplitude were maintained within physiologic ranges. This remains the primary human pharmacodynamic reference for CJC-1295 and established that GHRH receptor engagement can sustain GH/IGF-1 axis activity without disrupting pulsatile regulation.

Ipamorelin Selectivity — Foundational Pharmacology

PMID: 9849822 · Raun et al., Eur J Endocrinol 1998 · Evidence: Level IV (preclinical pharmacology)

The landmark study characterizing ipamorelin as "the first selective growth hormone secretagogue." In rats and conscious swine, ipamorelin produced potent, dose-dependent GH release with selectivity comparable to GHRH. Unlike GHRP-2 and GHRP-6 — which significantly elevated ACTH and cortisol alongside GH — ipamorelin produced no meaningful change in ACTH, cortisol, or prolactin at GH-stimulating doses. This selectivity profile defines ipamorelin's clinical appeal and differentiates it from earlier GHRP-class compounds. Note: this is preclinical data; human RCTs for ipamorelin in adults remain limited.

GHS in Hypogonadal Males — Systematic Review

DOI: 10.21037/tau.2019.11.30 · Sinha et al. 2020 · Evidence: Level III (systematic review)

This systematic review synthesized evidence on GH secretagogues — including ipamorelin and sermorelin — as adjunctive therapy in men with hypogonadism or metabolic syndrome. All compounds reviewed were identified as potent GH/IGF-1 stimulators with favorable body composition signals in preclinical and limited human data. The authors concluded that "a paucity of data examining clinical effects currently limits our understanding" and called for high-quality long-term RCTs. The review supports biological plausibility of body composition benefits without confirming them in controlled human trials.

Tesamorelin Body Composition Data — Contextual Evidence

PMID: 20554713 · Falutz et al., J Clin Endocrinol Metab 2010 · Evidence: Level I (Phase 3 RCT)

While not a direct study of CJC-1295/Ipamorelin, the tesamorelin Phase 3 RCT — demonstrating a −24 cm² reduction in visceral adipose tissue versus placebo in HIV+ patients with lipodystrophy — establishes that GHRH-class analog stimulation of the GH/IGF-1 axis can produce meaningful body composition changes in humans. This provides the strongest available human evidence for the GHRH analog mechanism as a class, informing the clinical rationale for CJC-1295 use. The extrapolation from tesamorelin in HIV lipodystrophy to CJC-1295 in healthy aging adults requires clinical judgment.

Dosing context — educational only

What is described in clinical settings — with caveats.

⚠ EDUCATIONAL ONLY — Not a Prescription. No FDA-Approved Protocol Exists.

Neither CJC-1295 nor ipamorelin is FDA-approved for any indication, and no FDA-approved dosing protocol exists. All dosing information below describes what is reported in clinical telehealth settings and is provided for educational purposes only. Dosing must be determined by a qualified prescribing clinician based on individual patient history, baseline IGF-1 levels, clinical goals, and ongoing monitoring. Self-administration without clinical supervision is not appropriate.

Standard Combination Dosing — Without DAC Version

In clinical telehealth settings, the most commonly described protocol uses CJC-1295 without DAC (Mod GRF 1-29) at 100–200 mcg paired with ipamorelin at 100–300 mcg per injection, administered subcutaneously. Timing is typically once or twice daily — frequently at bedtime to align with the natural nocturnal GH pulse, with an optional second administration in the morning or pre-workout in a fasted state. Standard cycle lengths range from 3–6 months, followed by a 4–8 week treatment break.

With-DAC Protocols — Different Frequency

When CJC-1295 with DAC is used, the extended half-life (6–8 days) changes the administration schedule to once or twice per week, rather than daily. DAC-version protocols are less commonly paired with daily ipamorelin due to the mismatch between CJC-1295's sustained action and ipamorelin's short action. Some protocols combine weekly DAC injections with nightly ipamorelin. Clinical preference varies, and your clinician will determine the most appropriate formulation and schedule for your situation.

IGF-1 Monitoring — Standard Practice

Baseline IGF-1 measurement before initiating any GHS protocol is considered standard of care in clinical settings. Follow-up IGF-1 at 4–8 weeks guides dose adjustment. The target is to support IGF-1 in a physiologically healthy range appropriate to the patient's age — not to achieve supraphysiologic levels. Dose increases should be guided by monitoring data, not by symptom response alone. HbA1c and fasting glucose monitoring is also appropriate, particularly in patients with pre-existing metabolic concerns.

Safety considerations

What is known — and what requires clinician evaluation.

GH secretagogue use is associated with a class-level side effect profile related to elevated GH and IGF-1. Individual compounds have distinct additional considerations. None of the following constitutes comprehensive safety information — clinician evaluation is required before initiating any GHS protocol.

Water Retention and Edema

Elevated GH promotes sodium and water reabsorption in the kidney, leading to fluid retention — typically manifest as peripheral edema (particularly in the hands and feet) or a general feeling of puffiness. This effect is most common during the first 1–2 weeks of treatment and usually resolves or diminishes significantly as the body adjusts. Dose reduction typically resolves persistent fluid retention.

Joint Discomfort and Carpal Tunnel Symptoms

GH-mediated fluid shifts can cause joint discomfort, swelling, and carpal tunnel syndrome-like symptoms (tingling or numbness in the hands and wrists). These effects are dose-dependent and typically reversible with dose adjustment. Patients with pre-existing joint conditions or carpal tunnel syndrome should discuss this risk explicitly with their clinician before initiating a GHS protocol.

IGF-1 Elevation and Acromegaly Risk

Chronically supraphysiologic IGF-1 levels — sustained far above the normal range for an individual's age — carry theoretical risk of acromegalic features including coarsening of facial features, joint enlargement, and soft tissue changes. This risk is primarily a concern with exogenous GH or with high-dose, long-duration GHS protocols without monitoring. Regular IGF-1 testing is the primary risk mitigation strategy. Evidence from clinical GHS use suggests IGF-1 typically rises within physiologic range at standard doses.

Glucose Metabolism — Monitor in At-Risk Patients

Elevated GH exerts anti-insulin effects, reducing peripheral glucose uptake and potentially raising fasting glucose. This effect is most clinically relevant in patients with pre-diabetes, insulin resistance, or type 2 diabetes. For healthy adults with normal glucose metabolism, short-term GHS use at standard doses does not typically produce clinically significant glucose dysregulation. HbA1c and fasting glucose monitoring is appropriate in any patient with metabolic risk factors.

Active Malignancy — Primary Contraindication

GH and IGF-1 have mitogenic (cell-growth promoting) activity. Use of any GH-elevating compound in patients with active cancer, or in patients with significant personal or family history of hormone-sensitive tumors, requires careful risk-benefit evaluation by an oncology-aware clinician. This is the primary theoretical long-term safety concern with GHS compounds. Clinician review of personal and family cancer history is a prerequisite for any GHS protocol.

Contraindications and Special Populations

Pregnancy and nursing: contraindicated due to absent safety data. Pituitary tumors or history of pituitary radiation: contraindicated (stimulating an already-compromised pituitary gland carries risk). Pediatric patients: not established. Patients on glucocorticoids: corticosteroids suppress GH secretion and may blunt response. Patients with active acromegaly: contraindicated. All contraindications require clinician evaluation — this list is not exhaustive.

Regulatory status — 2026

Not FDA-approved. Addressed via 503A compounding when clinically appropriate.

503A Compounding Status — Active FDA Review

CJC-1295 and ipamorelin are not FDA-approved for any indication. No USP monograph exists for either compound. Both have been nominated for the FDA's 503A bulk drug substances list and were under Category 1 active evaluation as of early 2026, meaning FDA was actively reviewing them for potential listing. The FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026 is expected to address multiple peptides, including GH secretagogues. Legal compounding under 503A requires the compound to appear on the FDA-approved bulks list. Current compounding status should be confirmed with a licensed compounding pharmacy and compliance counsel at the time of your consultation.

503A Compounding — What It Means

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists or physicians to compound drugs for individual patients based on valid prescriptions when certain conditions are met. Key requirements include: the drug must be on the FDA-approved 503A bulk drug substances list (or qualify for specific exemptions); it must be compounded by a licensed compounding pharmacy; and it must be prescribed by a licensed practitioner for a specific patient's clinical need. When CJC-1295 or ipamorelin are on the bulks list, 503A compounding provides the legal framework for patient access through licensed telehealth programs.

WADA Prohibited Status

Both CJC-1295 and ipamorelin are prohibited in competitive sports under the WADA Prohibited List, classified as peptide hormones and related substances. This classification is independent of FDA compounding regulation. Competitive athletes in sanctioned sports should not use these compounds and should verify current WADA prohibited list status before any hormone-related protocol. Clinical use by non-athletes is not affected by WADA classification.

How YourHealthRx approaches it

Clinician-supervised, evidence-informed, and nationally accessible.

Our Clinical Approach to GH Secretagogue Protocols

YourHealthRx connects patients with licensed clinical partners nationwide — serving patients across all 50 states and DC through HIPAA-compliant telehealth infrastructure. Our partner clinicians approach CJC-1295/Ipamorelin protocols with a full clinical intake including medical history review, hormone panel assessment (baseline IGF-1, fasting glucose, HbA1c, and other relevant labs), cancer risk screening, and an individualized protocol design. No one-size-fits-all dosing. Every protocol is tailored to the patient's specific baseline and health goals.

GHS peptides are dispensed exclusively through licensed 503A compounding pharmacies when clinically appropriate and when the compounds' compounding status is compliant with current FDA guidance. Our clinical partners maintain current awareness of FDA regulatory developments — including the July 2026 PCAC meeting outcomes — and update protocols as the regulatory landscape evolves. Ongoing monitoring including IGF-1 follow-up and clinical check-ins is built into every protocol.

FAQ

Common questions about CJC-1295 and ipamorelin.

What is the difference between CJC-1295 with DAC and without DAC?

The without-DAC form (Mod GRF 1-29) has a ~30-minute half-life and produces a discrete, pulsatile GH surge that mimics natural physiology. The with-DAC form extends the half-life to 6–8 days via albumin binding, producing sustained GH elevation. The without-DAC version is preferred in combination protocols because it preserves physiologic GH pulsatility and feedback regulation.

Why is ipamorelin preferred over older GHRPs?

Ipamorelin's defining advantage is receptor selectivity — it stimulates GH release without meaningfully elevating cortisol, ACTH, or prolactin. Older compounds like GHRP-2 and GHRP-6 produced significant HPA axis side effects. Ipamorelin's selectivity profile was established in the foundational 1998 Raun et al. study (PMID: 9849822), making it the clinical standard in combination GHS protocols.

How does the combination produce more GH than either compound alone?

CJC-1295 activates pituitary GHRH receptors via the cAMP/PKA pathway; ipamorelin activates GHS-R1a via Gq/phospholipase C signaling. Co-activation of both distinct pathways produces a synergistic GH pulse — greater than either agent alone. This dual-pathway mechanism is why the combination is the standard clinical approach rather than monotherapy with either compound.

Is CJC-1295/Ipamorelin FDA-approved?

No. Neither compound is FDA-approved for any indication. Both are addressed via 503A compounding when clinically appropriate and when compounds appear on the FDA-approved bulks list. Regulatory status was under active FDA evaluation as of mid-2026; consult your clinician for current compliance status at the time of your consultation.

What side effects should I discuss with my clinician?

The most common are water retention, joint discomfort, and carpal tunnel-like symptoms — all GH-mediated and dose-dependent. Increased appetite (via ghrelin receptor activation by ipamorelin) is common. Glucose monitoring is appropriate in metabolically at-risk patients. The primary serious consideration is active malignancy — GH and IGF-1 are mitogenic, requiring oncology-aware clinician review of cancer history before initiating any GHS protocol.

How long before I notice any effects?

IGF-1 levels typically rise within 2–4 weeks, confirming pharmacological response. Sleep quality improvements are often reported within the first 2–4 weeks of nightly dosing. Body composition changes — reduced fat, improved lean mass — are generally noticed at 8–12 weeks, with more pronounced changes at 3–6 months. Individual response varies significantly based on baseline GH/IGF-1 status, age, and lifestyle.

Why do I need IGF-1 monitoring?

IGF-1 monitoring confirms that the protocol is achieving a pharmacological response (and can identify non-responders), guides dose titration, and ensures levels remain within a physiologically healthy range for the patient's age. Chronically supraphysiologic IGF-1 carries theoretical risk of acromegalic features. Monitoring IGF-1 at baseline, 4–8 weeks, and periodically throughout treatment is the primary safety tool for any GHS protocol.

Are CJC-1295 and ipamorelin banned in sports?

Yes — both are prohibited under the WADA Prohibited List as peptide hormones and related substances. This applies in all sanctioned competitive sports. Clinical use by non-athletes is not affected by WADA classification. Athletes should verify current WADA prohibited list status directly before any peptide protocol, as the list is updated annually.

Informational only. Content on this page is for informational purposes and does not constitute medical advice. CJC-1295 and ipamorelin are not FDA-approved for any indication. Compounding availability depends on current 503A regulatory status — confirm with your clinician at the time of consultation. All prescriptions are issued at the sole discretion of the prescribing clinician. Not all compounds are available in all states. Last reviewed: May 2026.

Sources

References cited on this page.

Primary References

  • Ionescu & Frohman (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. PMID: 17018654
  • Raun et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PMID: 9849822
  • Sinha et al. (2020). Clomiphene citrate and growth hormone secretagogues in the treatment of hypogonadism. Transl Androl Urol. DOI: 10.21037/tau.2019.11.30
  • Falutz et al. (2010). Tesamorelin Phase 3 pooled analysis. J Clin Endocrinol Metab. PMID: 20554713

Related

Continue exploring.

Sermorelin

The original GHRH analog with the longest clinical safety record. Shorter-acting than CJC-1295, with a well-established compounding history. A common first-step GHS option for patients new to GH secretagogue protocols.

Read the Sermorelin Page

Tesamorelin

The only FDA-approved GH secretagogue (Egrifta®), with Phase 3 RCT data demonstrating meaningful visceral fat reduction. The strongest evidence in the GHS class — important context for understanding the GHRH analog mechanism.

Read the Tesamorelin Page

Start a Clinical Evaluation

A licensed clinician can evaluate your baseline IGF-1, metabolic health, and clinical history to determine whether a CJC-1295/Ipamorelin protocol may be appropriate for your goals. Available nationwide across all 50 states and DC.

Start Your Intake

Evidence-informed. Clinician-supervised. Nationwide.

A licensed clinician evaluates your baseline and designs an individualized GHS protocol — not a one-size-fits-all template.

CJC-1295/Ipamorelin protocols require baseline IGF-1 assessment, cancer risk screening, and ongoing monitoring. Our partner clinicians operate across all 50 states and DC, with full HIPAA-compliant telehealth intake.

Start Your Intake Back to GH Secretagogues